Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

and VA111913 for dysmenorrhoea, product candidates which directly target the causes of conditions that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia was spun out from Ferring Research Ltd in 2008 and its pipeline is driven by the proven small molecule drug discovery and development capabilities of that unit and Vantia's experienced management team. Vantia's strategy is to develop candidates to Phase II proof-of-concept and then commercialise through partnerships. The Company is well-funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.

http://www.vantiatherapeutics.com.

About VA106483 and nocturia:

VA106483 is a novel small molecule drug candidate in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep. VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin 2 receptors, decreasing urine volume. Clinical data indicate that VA106483 is generally well tolerated and an effective anti-diuretic that increases urine concentration and reduces urine output.

Vantia's initial indication for VA106483 is nocturia. A Phase II clinical programme has been designed and trials are underway, with initial results expected mid 2009.

Nocturia is commonly associated with benign prostatic hypertrophy (BPH) where it is estimated to affect up to 70% of BPH patients. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need and estimated to be worth in excess of US$500m per annum. This market opportunity presents only part of
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 e2b teknologies , ... located in Northeast Ohio, today announced a leading independent ... support its upgrade to the latest version of ... group practice of its kind in the region, the ... of transactions, so efficiency and data accessibility are paramount ...
(Date:3/5/2015)... Texas (PRWEB) March 05, 2015 ... of acute and chronic orthopedic conditions such as ... knee, tennis elbow, and joint pain due to ... be administered during orthopedic surgeries to promote better ... scientific advances in nearly pain-free bone marrow harvesting ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... 13 Proteon,Therapeutics, Inc. ( http://www.proteontherapeutics.com ), announced ... the European Patent Office. The patent,(No. 1220830) covers ... as elastases for,dilating arteries and veins in humans. ... in June and December of 2006. Proteon Therapeutics,owns ...
... has received its second Frost & Sullivan Technology Award ... the Frost & Sullivan Awards Banquet,Signalife was awarded the ... Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, and its ... accept the award., Signalife, Inc. is in a ...
... Advancing Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... 13 Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved ...
Cached Biology Technology:Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins 2Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Shenzhen, China The Asian Cancer Research Group ... and Company, Merck (known as MSD outside the ... with BGIthe world,s largest genomics organizationtoday announced the ... of recurrent hepatitis B virus (HBV) integration in ...
... researchers have known for well over a century that different ... one has been able to determine the mechanisms of organ ... New details that could help shed light on this hypothesis ... Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, ...
... new study, children exposed to high levels of the ... chromosomal aberrations (CAs), which have been previously associated with ... and long-lasting subtype of CAs. Researchers from the ... Mailman School of Public Health, Columbia University Medical Center, ...
Cached Biology News:ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 2ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 2Cancerous tumors deliver pro-metastatic information in secreted vesicles 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 4Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3
Request Info...
Special grade: for electrophoresis...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
Biology Products: